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The objective of this randomised, controlled, parallel-group monocentric clinical trial was to assess the
efﬁcacy (at low and high dose) and the safety (at high dose) of a recombinant canarypox virus (ALVAC)
expressing feline interleukin 2 (IL-2). ALVAC IL-2 was administered to cats as an adjunct treatment of
feline ﬁbrosarcoma in complement to surgery and brachytherapy (reference treatment). Seventy-one cats
with a ﬁrst occurrence of feline ﬁbrosarcoma were referred to the Veterinary Oncology Centre for
post-surgical radiotherapy. They were randomly assigned to three treatment groups: reference treatment
group (23 cats), ALVAC IL-2 low dose group (25 cats) and ALVAC IL-2 high dose group (23 cats). Two dos-
ages of ALVAC IL-2 were used to assess both safety (high dose) and efﬁcacy (high and low doses). The
treatment consisted of six consecutive doses of ALVAC IL-2 administered subcutaneously at the tumour
site on Day 0 (one day before brachytherapy treatment), Day 7, Day 14, Day 21, Day 35 and Day 49. All
cats were evaluated for relapse (i.e. local tumour recurrence and/or metastasis) every three months for at
least one year (ALVAC IL-2 high dose group) or two years (reference treatment and ALVAC IL-2 low dose
groups) by complete physical examination and regular CT scans. ALVAC IL-2 treatment was well tolerated
and adverse effects were limited to mild local reactions. ALVAC IL-2 treatment resulted in a signiﬁcant
longer median time to relapse (>730 days in the ALVAC IL-2 low dose group) than in the reference
treatment group (287 days), and a signiﬁcant reduction of the risk of relapse by 56% at one year (ALVAC
IL-2 treatment groups versus reference treatment group) and 65% at two years (ALVAC IL-2 low dose
treatment group versus reference treatment group).
 2014 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/3.0/).1. Introduction
Feline injection-site sarcomas (FISS) are aggressive cutaneous
mesenchymal tumours and represent 6–12% of all feline tumours
[1]. Although the pathogenesis of this tumour is not fully under-
stood, it is currently accepted that, in genetically predisposed cats,
a traumatism causing inﬂammation in the subcutis (i.e. injection)
may trigger the development of FISS. Aggressive and complete sur-
gical excision was the treatment of choice [2–4]. However, because
of the invasive nature of FISS, the recurrence rate is high rangingfrom 30% to 75%, with metastasis occurring in 6–25% of affected
cats [3,5,6]. Adjunct treatments such as pre or post-operative radi-
ation therapy and chemotherapy are used but their efﬁcacy has not
always been experimentally demonstrated [8]. Currently, the treat-
ment of choice consists in an aggressive surgery combined with
radiation therapy [6,9]. Despite this treatment, local recurrences
are still observed in a high proportion of the patients. Any therapy
that could further reduce the rate of relapse would therefore be
useful for veterinary oncologists.
Immunotherapy has been investigated in two previous studies
in cats with FISS.
Local IL-2 therapy has been shown to be efﬁcacious against var-
ious tumours including FISS. When combined with surgery and
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secreting human IL-2 reduced the rate of relapse and increased
the median survival time [10]. Similar results were observed with
repeated local injections of either the canarypox virus vector
(ALVAC) or the genetically attenuated vaccinia virus vector
(NYVAC) expressing feline IL-2 or human IL-2, respectively [11].
The ﬁrst objective of this new study was to conﬁrm the efﬁcacy
of an ALVAC-IL2 construct over a longer period (two-year follow-
up). Second objective was to conﬁrm its safety at high dose. ALVAC
IL-2 was administered to cats as an adjunct treatment of FISS in
combination with surgery and brachytherapy.2. Materials and methods
2.1. Animals
The study was a randomized, controlled, parallel-group, mono-
centric safety and efﬁcacy study. It took place at the Veterinary
Oncology Centre of Maisons-Alfort, France from October 2006 to
October 2012. Eligible patients were cats in good general condition
with a ﬁrst occurrence of FISS having undergone surgical excision
and presented to the Centre for a brachytherapy treatment. Surgi-
cal excision was performed by several veterinary practitioners and
there was no standardized surgical procedure. Tumour size had to
be between 2 and 5 cm (size measured with a caliper by the
pathologist on the ﬁxed formalin sample). Histological analysis
was performed or reviewed at the Veterinary Histo-Cytopathology
Laboratory (France) to conﬁrm the nature of the tumour and assess
the status of the surgical margins. The margins were evaluated on
four full thickness sections on the vertical plan (anterior, posterior
and lateral margins) and one complete section of deep muscular
layers on the horizontal plan (deep margin). Margin results were
deﬁned as clean (complete) or dirty (incomplete or close) margins.
Only cats with no pulmonary metastasis or enlarged lymph nodes,
no macroscopic disease and no wound healing complications were
enrolled. The absence of previous adjunct treatment (radiotherapy,
chemotherapy, immunotherapy or genetic therapy), of corticoste-
roids treatment within 1 month (long acting corticosteroid) or
1 week (short acting corticosteroid) prior to enrollment was
another prerequisite.
At the time of enrolment, all cats underwent a full clinical
examination including serum biochemistry, complete blood cell
(CBC) count, urine density and screening for FeLV antigens and
FIV antibodies and a computed tomography (CT) scan of the
tumour area and thorax.
As tumour ablation completeness is considered a key prognostic
factor [3,7,12], cats were randomly assigned to three treatment
groups using permuted-block randomization stratiﬁed on the sta-
tus of the surgical margins assessed by histological analysis: con-
trol group, ALVAC IL-2 low dose and ALVAC IL-2 high dose. For
ethical reasons and to avoid any bias in the study, no placebo could
be administered to the control animals. Indeed, these cats are
highly sensitive to any injection or traumatism and administration
of a placebo would likely increase the rate of relapse in the con-
trols. Consequently, only the pet owners were maintained blind
to the treatment group.
Written consent for entry to the trial was provided for each cat’s
owner. Cats were managed similarly and with due regard for their
well being.Fig. 1. Modalities of treatment administration. After reconstitution of the lyophil-
isate with the solvent, ﬁve injections (each approximately 0.2 mL – blue arrows)
were administered subcutaneously around the tumour excision site: one injection
at each corner and one injection at the centre of a 5  5 cm square centred on the
middle of the surgical scar. (For interpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web version of this article.)2.2. Products
Recombinant canarypox virus expressing feline interleukin 2
gene (ALVAC IL-2) was provided by Merial, France. The virus
was grown in chicken embryo ﬁbroblasts. Vaccine consisted of aclariﬁed viral suspension, which was freeze-dried and kept at
+4 C until use. The lyophilisate containing between 106.0 and
108.3 ELISA Infectious Dose 50% (EAID50)/dose was diluted in
1 mL of water for injection immediately before use.
2.3. Immunotherapy
The treatment protocol consisted in six consecutive doses of
less than 106.5 EAID50 ALVAC IL-2/dose in low dose group or up
to 108.3 EAID50 ALVAC IL-2/dose in high dose group over 7 weeks.
Cats from treated groups received one dose once a week for
4 weeks followed by once every 2 weeks for the last two doses
(i.e. on Days 0, 7, 14, 21, 35 and 49). The ﬁrst dose was adminis-
tered on the day before radiotherapy (i.e. about one month after
surgery). Each dose of ALVAC IL-2 was administered subcutane-
ously around the tumour excision site (0.2 mL at the centre and
0.2 mL at each corner of a 5  5 cm square centered on the middle
of the surgical scar (see Fig. 1) using a same 0.50 mm needle gauge.
No anesthesia or tranquilization was required for the treatment
administration. Cats were observed for approximately 15 min post
treatment for any immediate local or general adverse reactions.
2.4. Radiotherapy
All cats received an iridium-based brachytherapy (high dose
rate technique). Distribution of the dose was planned by 3D treat-
ment planning software (Eclipse™, Varian). Four fractions of 6.5 Gy
each were delivered at 6 mm from the radioactive source at Day 1,
Day 1 + 8 h, Day 3 and Day 3 + 8 h, respectively, by using intersti-
tial plastic ﬂexible needles with mandrin (diameter 2 mm, length
113 mm, Varian) for a total equivalent dose of 60 Gy according to
the linear quadratic model.
For each therapy session, cats were anesthetised with 4 mL/5 kg
of propofol (Propofol Lipuro 1%, B Braun Médical or Rapinovet,
Merck Animal Health) by intravenous route.
2.5. Follow-up
Cats treated with the high dose of ALVAC IL-2 were followed for
only one year (because the main objective for this group was to
evaluate the safety) and the low dose and the control groups were
followed for two years.
The time to relapse was recorded for all cats (see deﬁnition
below).
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and local and systemic reactions were monitored in cats treated
with the high dose ALVAC IL-2.
The follow-up consisted in a complete physical examination at
the Oncology Centre every 3 months for at least 1 year (high dose
ALVAC IL-2 treated cats) and 2 years (low dose ALVAC Il-2 treated
cats and controls). In case of relapse notiﬁed by the client or the
veterinarian, the cat was brought to the Oncology Centre for a full
examination. A CT-scan of the excision site and the thorax was per-
formed at 3, 6, 12 (all groups) and 24 (low dose treated and control
groups) months after enrolment. Cats were anesthetised with
4 mL/5 kg of propofol (Propofol Lipuro 1%, B Braun Médical or
Rapinovet, Merck Animal Health) for the CT-scan. CBC count
and serum biochemistry were performed on Days 1, 21, 49 for
the high dose treated group and on 3 months and 6 months post-
enrolment for all cats.2.6. Data analysis
Prior the efﬁcacy analysis, the groups were checked for
comparability on the baseline criteria: completeness of tumour
ablation (v2) and interval between tumour ablation and enrolment
(ANOVA).
The primary efﬁcacy endpoint was the time until relapse (dis-
ease-free interval, DFI) deﬁned by the time in days between Day
0 and relapse. A relapse was deﬁned as a recurrence of the primary
tumour (identiﬁed by palpation or by CT-scans) and/or pulmonary
or regional lymph nodes metastasis (identiﬁed by CT-scans). The
appearance of another FISS at a different site was not considered
as a relapse. Recurrence of primary tumours were conﬁrmed by
the Veterinary Histo-Cytopathology Laboratory who was blinded
to the treatment group. Time of relapse was the ﬁrst day of suspi-
cion (date of the clinical examination or day of the CT-scan). Cats
withdrawn, dropped out or dead for any other reason than FISS
were considered right-censored and the date of the last known
observation was taken into account in the analysis.
A Proportional Hazards Cox regression model was ﬁtted to DFI
data to assess the effect of ALVAC IL-2 treatment while controlling
for the type of surgical margin by computing the Hazard Ratio (HR)
and its 95% conﬁdence interval for the group. The result is inter-Table 1
Characteristics of the cats and individual results.
Sex Age Breed Tumour
localization
Surgical
margins
Estimated time betwee
surgery and Day 0
Control group
F* 4.8 EUROPEAN Interscapular Clean 39
M* 9.9 EUROPEAN Flank Clean 53
M* 9.2 EUROPEAN Shoulder Clean 24
M* 6.6 EUROPEAN Interscapular Clean 41
M* 12.5 EUROPEAN Thorax Clean 20
F* 9.9 EUROPEAN Interscapular Clean 20
M* 9.4 EUROPEAN Interscapular Clean 19
M* 14.4 EUROPEAN Interscapular Clean 54
F* 4.0 EUROPEAN Shoulder Clean 25
M* 9.2 EUROPEAN Thorax Dirty 13
M* 11.9 EUROPEAN Shoulder Dirty 28
M* 6.9 EUROPEAN Thorax Dirty 31
M* 8.3 EUROPEAN Flank Dirty 18
F* 14.1 EUROPEAN Interscapular Dirty 20
M* 10.5 PERSIAN CROSSED Lumbar Dirty 62
M* 7.6 EUROPEAN Interscapular Dirty 49
F* 9.3 EUROPEAN Thorax Dirty 52
M* 6.9 EUROPEAN Flank Dirty 27
M* 6.6 EUROPEAN Flank Dirty 38
F* 13.8 EUROPEAN Thorax Dirty 13preted in terms of reduction (in percent) of the hazard of relapse
in treated cats and calculated as [1  HR]  100. The Kaplan–Meier
Product-Limit method was used to plot the survival curves and to
compare the median DFI (Log-rank test).
As a secondary efﬁcacy endpoint, we also assess the ALVAC IL-2
treatment on the relapse rate calculated at ﬁnal time-point (1 or
2 years) over completers as cats who had a recurrence or a metas-
tasis among cats who completed the study with or without relapse.
The treatment efﬁcacy was estimated while controlling for the
type of surgical margin using a Cochran–Mantel–Haenszel test.
The efﬁcacy analyses were performed on a intent-to treat basis
and were conducted over the one- and the two-year follow-up
periods independently. For the one-year follow-up period the
two treated groups (i.e. high and low doses) were combined after
checking their comparability.
The absence of toxic side effect was checked by comparing
descriptively for each cat the post-treatment values for CBC count
and serum biochemistry to those obtained at the time of enrolment.
All analyses were two-tailed and conducted with SAS 9.2 (SAS
Institute Inc, Cary, NC). The type I error was set to a = 5%.3. Results
Seventy-one cats (67 European, 1 Persian crossed, 1 Burmese, 1
Russian Blue cat and 1 Siamese – 39 neutered males, 31 spayed
females and 1 female) aged between 4 and 17 years (mean,
10 years) met all the inclusion criteria and were enrolled. The
tumours ranged from 2 to 5 cm and were usually located in the
interscapular region (34). Other sites were the thoracic (10),
abdominal (16), shoulder (6), lumbar (4) or the thigh region (1).
The histological analysis showed that 42 cats had dirty surgical
margins (incomplete tumour resection) and 29 had clean surgical
margins. A CT-scan of the tumour area and thorax conﬁrmed that
all cats were free of metastasis before inclusion. Cats were ran-
domly allocated to the control group (23 cats), ALVAC IL-2 low
dose (25 cats) and ALVAC Il-2 high dose (23 cats). Characteristics
of the cats are shown in Table 1.
Groups were comparable on the baseline criteria (Table 2).
Eight cats were right-censored for the DFI analysis because of
death for ﬁbrosarcoma unrelated causes (4 cats), lost to follow-n DFI Relapse within
1 year
Relapse within
2 years
182 Yes Yes
778 No No
602 No Yes
197 Yes Yes
190 Yes Yes
774 No No
196 Yes Yes
287 Yes Yes
637 No Withdraw (Lost to follow-up)
721 No No
7 Yes Yes
756 No No
98 Yes Yes
175 Yes Yes
739 No No
735 No No
732 No No
35 Yes Yes
49 Yes Yes
273 Yes Yes
(continued on next page)
Table 1 (continued)
Sex Age Breed Tumour
localization
Surgical
margins
Estimated time between
surgery and Day 0
DFI Relapse within
1 year
Relapse within
2 years
F* 11.9 EUROPEAN Interscapular Dirty 49 728 No No
F* 6.6 EUROPEAN Shoulder Dirty 46 175 Yes Yes
M* 7.4 EUROPEAN Interscapular Dirty 33 792 No No
Low dose ALVAC IL2 group
M* 11.7 EUROPEAN Flank Clean 12 22 Withdraw Withdraw (Other localization of FISS)
F* 11.1 EUROPEAN Interscapular Clean 38 763 No No
F* 9.3 EUROPEAN Flank Clean 25 760 No No
M* 4.5 EUROPEAN Thorax Clean 35 742 No No
F* 12.6 EUROPEAN Flank Clean 35 724 No No
M* 7.2 EUROPEAN Interscapular Clean 76 26 Withdraw withdraw (Death by strangulation)
M* 10.7 EUROPEAN Thigh Clean 55 749 No No
F* 7.9 EUROPEAN Interscapular Clean 41 161 Yes Yes
F* 10.7 EUROPEAN Flank Clean 59 756 No No
M* 14.2 EUROPEAN Thorax Clean 39 204 Withdraw Withdraw (Euthanasia – diabetes complication)
F* 8.5 EUROPEAN Interscapular Clean 60 408 No Withdraw (Lost to follow-up)
M* 7.0 EUROPEAN Interscapular Dirty 12 729 No No
F* 5.2 EUROPEAN Flank Dirty 34 91 Yes Yes
M* 13.3 EUROPEAN Interscapular Dirty 45 112 Yes Yes
M* 8.8 EUROPEAN Interscapular Dirty 33 749 No No
M* 5.6 EUROPEAN Interscapular Dirty 14 21 Yes Yes
M* 5.2 EUROPEAN Interscapular Dirty 45 735 No No
M* 10.1 EUROPEAN Interscapular Dirty 24 732 No No
M* 13.3 EUROPEAN Flank Dirty 68 99 Withdraw Withdraw (dead from liver tumour)
F 9.0 EUROPEAN Flank Dirty 55 182 Yes Yes
F* 6.8 EUROPEAN Shoulder Dirty 34 770 No No
M* 9.0 BURMESE Lumbar Dirty 32 735 No No
F* 12.5 EUROPEAN Interscapular Dirty 21 763 No No
F* 8.2 SIAMESE Interscapular Dirty 82 98 Withdraw Withdraw (Other localization of FISS)
F* 17.0 EUROPEAN Lumbar Dirty 31 555 No Withdraw (Euthanasia – anal carcinoma)
High dose ALVAC IL2 group
M* 12.1 EUROPEAN Interscapular Clean 13 379 No NA
M* 6.6 RUSSIAN BLUE CAT Thorax Dirty 27 364 No NA
M* 13.3 EUROPEAN Interscapular Clean 27 275 Yes NA
F* 13.6 EUROPEAN Interscapular Clean 32 372 No NA
F* 10.7 EUROPEAN Flank Clean 44 370 No NA
M* 10.6 EUROPEAN Interscapular Clean 47 364 No NA
M* 12.1 EUROPEAN Thorax Clean 41 364 No NA
M* 11.1 EUROPEAN Interscapular Clean 10 368 No NA
F* 11.9 EUROPEAN Interscapular Clean 24 385 No NA
M* 8.8 EUROPEAN Shoulder Clean 48 350 No NA
F* 9.4 EUROPEAN Interscapular Dirty 26 182 Yes NA
F* 13.0 EUROPEAN Thorax Dirty 24 189 Yes NA
F* 9.4 EUROPEAN Interscapular Dirty 27 368 No NA
M* 7.1 EUROPEAN Flank Dirty 32 366 No NA
F* 13.0 EUROPEAN Interscapular Dirty 42 98 Yes NA
F* 9.0 EUROPEAN Interscapular Dirty 40 91 Yes NA
F* 10.4 EUROPEAN Flank Dirty 49 379 No NA
M* 11.5 EUROPEAN Interscapular Dirty 46 91 Yes NA
F* 10.6 EUROPEAN Flank Dirty 45 364 No NA
M* 7.7 EUROPEAN Lumbar Dirty 45 182 Yes NA
F* 9.3 EUROPEAN Interscapular Dirty 49 364 No NA
F* 7.3 EUROPEAN Flank Dirty 31 368 No NA
M* 7.0 EUROPEAN Interscapular Dirty 46 378 No NA
* Castrated or spayed.
Table 2
Groups comparability before treatment.
Control group ALVAC IL-2 low dose group ALVAC IL-2 high dose group Groups comparability
Delay between tumour ablation and post-operative radiotherapy
(in days): range (mean/median)
13–62 (34/31) 12–82 (40/35) 10–49 (35/40) p = 0.320a
Numbers of cats with dirty margins/total cats (% of dirty margins) 14/23 (61%) 14/25 (56%) 14/23 (61%) p = 0.924b
a ANOVA.
b v2 test.
4 D. Jas et al. / Trials in Vaccinology 4 (2015) 1–8up (2 cats) or secondary FISS at a different site (2 cats). One cat pre-
sented a second FISS starting 7 days after Day 0 at a distant site
(right axilla) from the primary tumour (right ﬂank). The other cat
presented on Day 0, a nodular lesion, visible on the CT-scan. As this
lesion was not organized (only an heterogeneity in the left trape-zius muscle thickness), it was not suspected to be a ﬁbrosarcoma.
Three months later this lesion had evolved and was tinted by the
contrast medium at CT-scan. This mass was conﬁrmed to be a FISS.
This lesion was neither the initial tumour which was not entirely
removed, nor a recurrence, as the locations of the tumours were
Table 3
Relapse rate.
Type of relapse Rate of relapse (%) p valuea
1-Year analysis Control (n = 23) 9 Recurrence, 3 metastasis 52.2 0.052
Treated (low and high dose ALVAC IL-2) (n = 43) 7 Recurrence, 3 metastasis, 2 recurrence & metastasisb 27.9
2-Year analysis Control (n = 22) 10 Recurrence, 3 metastasis 59.1 0.053
Treated (low dose ALVAC IL-2) (n = 18) 3 Recurrence, 2 metastasis 27.8
a Cochran–Mantel–Haenzel test.
b Low dose ALVAC IL-2 (3 recurrence, 2 metastasis) and high dose ALVAC IL-2 group (4 recurrence, 1 metastasis, 2 recurrence & metastasis).
Fig. 2. Survival curves per group at one-year (group A = control group; group B = low dose ALVAC IL-2 treated group; group C = high dose ALVAC IL-2 treated group – left:
groups A, B and C; right: groups A and B + C).
Fig. 3. Survival curves per group at two-years (group A = control group; group
B = low dose ALVAC IL-2 treated group).
Table 4
DFI analysis.
Med
1-Year analysis Control (n = 23) 287
Treated (low and high dose ALVAC IL-2) (n = 48)
2-Year analysis Control (n = 23) 287
Treated (low dose ALVAC IL-2) (n = 25)
a Log-rank test.
b Cox model.
D. Jas et al. / Trials in Vaccinology 4 (2015) 1–8 5distant (by around 4 cm) and there was no macroscopic lesion
between the initial tumour and the new lesion. All other cats were
followed-up until relapse for one (high dose ALVAC Il-2) or two
years (control and low dose ALVAC IL-2) after enrolment.
The treatment was well tolerated even after administration of a
high dose of ALVAC IL-2. No immediate general reaction and a
single immediate local reaction attributable to the product were
reported (pain on palpation in one cat). Delayed general reactions
that were not attributed to another cause were apathy (with no
other associated signs) in two cats at one or two occasions, vomit-
ing in one cat and diarrhoea in two cats. Delayed local reactions
were limited to a moderate pain in one cat and minor events such
as crusts, scratching, alopecia or papule in 6 cats receiving the
ALVAC IL-2 at high dose.
There was no signiﬁcant variation in the biochemical and hema-
tological parameters of treated cats.
ALVAC IL-2 tended to reduce signiﬁcantly the frequency of
relapse at one year post-treatment (52.2% of relapse in the controls
versus 27.9% in treated cats, p = 0.052) and at two years post-
treatment (59.1% of relapse in the controls versus 27.8% in treated
cats, p = 0.053) (Table 3). At one year post-treatment, the perfor-
mance of ALVAC IL-2 was similar in the low-dose and in theian DFI (p valuea) HR [95% HR conﬁdence limits] (p valueb)
days versus > 365 days (0.048) 0.44 [0.197–0.981] (0.0447)
days versus > 730 days (0.046) 0.353 [0.126–0.992] (0.0483)
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and the median DFI was not reached whichever the treatment
(Fig. 2). In the absence of signiﬁcant difference between the low-
dose and high-dose treatments, the comparison after one year of
treatment was made between all treated cats and controls.
The median DFI was 287 days for the control group and higher
than 365 days (one-year analysis) or higher than 730 days
(two-years analysis) for treated cats (Figs. 2 and 3).
Our results show that the ALVAC IL-2 treatment is efﬁcacious
and reduced the risk of relapse over one year by 56% and over
two-years by 65% in treated cats compared to controls (HR = 0.44,
p = 0.045 for one-year analysis and HR = 0.35, p = 0.048 for
two-years analysis, respectively) (Table 4).4. Discussion
The efﬁcacy of ALVAC IL-2 as an adjunct therapy for FISS has
been demonstrated over a one-year follow-up [11]. However, it
was important to conﬁrm the efﬁcacy over a longer period of time.
Indeed, different recurrence rates at one and two years post-treat-
ment have been reported with some studies [6]. Evaluating the
dose effect on both the efﬁcacy and safety of the product was the
second objective. Since the safety of ALVAC is related to the vector
viral titre, the absence of negative impact of the administration of a
high dose to cats that are reported to be very sensitive to any local
inﬂammation was checked.
In addition, after the initial study, the method of administration
of the ALVAC IL-2 was optimized. The local expression of IL-2 in the
subcutaneous tissue of a 5  5 cm area was measured by quantita-
tive RT-PCR after administering one dose (1 mL) of ALVAC IL-2 in
the centre of the square or after splitting it in ﬁve points (0.2 mL
injected in the centre and in the four corners). Overall, local IL-2
expression was higher with the 5 injections points procedure (data
not shown). This method of administration was then applied in our
efﬁcacy and safety trial. To standardize the treatment and avoid
any difﬁculty in the interpretation of the results, ALVAC IL-2 was
administered according to the same distribution in all cats. We
may expect a distribution ﬁtting more with the shape of the
tumour bed to be potentially more efﬁcacious.
Anti-tumour responses have been shown to be stronger when
IL-2 is administered locally several times [13]. To achieve a sus-
tained local expression of IL-2, administrations of ALVAC IL-2 were
repeated over time. This regimen was based on the local persis-
tence of the virus at the site of administration (about 4 days)
and, consecutively, the transient expression of the transgene for
several days (canarypox virus is not replicative in mammals) [14].
The selection criteria for the enrollment of the patients were
restrictive to avoid any bias in the analysis and conclusions of
the study. Only cats with a primary tumour within the same lim-
ited size range and without metastasis or lymph node enlargement
were enrolled. Since the quality of the surgery is a key factor of
success for the treatment [3,7,12], the status of the surgical margin
assessed by histological examination with the same pathologist
was taken into account in the design of the trial (through the ran-
domization scheme) and the statistical analysis. Importantly as
well, the interval between surgery and initiation of radiotherapy
was similar between the treatment groups. Indeed, a longer inter-
val between surgery and radiotherapy has been reported to have a
negative effect on the outcome of the treatment [6]. Overall, the
cohort of patients enrolled in this study was representative of
the feline population likely to develop FISS.
ALVAC IL-2 treatment resulted in a longer median time to
relapse (>730 days) than in controls (287 days) and a reduction
of the risk of relapse by 56% after one year and 65% after 2 years
compared to controls. No ALVAC IL-2 dose effect was observedwhich is consistent with the absence of clear dose–response of
local IL-2 reported by others [15,16]. IL-2 is efﬁcacious locally at
relatively low doses, equivalent to 103 to 105 IU IL-2 [16]. On the
basis of in vitro expression in feline cells, and consistently with
other estimations [17], ALVAC IL-2 dosage (between 106 and 107
EAID50) corresponds to a local expression estimated between 103
and 104 IU IL-2.
Importantly, our study results were consistent with Jourdier’s.
In that study, the cats were treated according to the same regimen
at a dose of 106.7 CCID50 ALVAC IL-2/dose (1 CCID50 # 1 EAID50). The
rates of relapse at one year in the controls and treated animals
were very comparable in the two studies (61% and 52% in Jourdier’
and our controls respectively, 28% in treated animals in both stud-
ies). It should be noted that only cats with primary tumours were
enrolled in our study and this could explain the slightly lower
relapse rate observed in controls. The similarity of the results
between the two studies demonstrated the robustness of ALVAC
IL-2 treatment over a wide range of ALVAC titres.
DFI in control cats was lower than DFI reported in other studies
investigating surgery and post-surgery radiotherapy [5, 6]. In our
study, surgical excision was done by the referring practitioner for
all cats, whereas a fraction of the cats in Bregazzi and Cohen’s stud-
ies underwent surgery at the university (60% and 37%, respec-
tively). This may have a strong impact on the DFI [3]. In Cohen’s
study, cats that had conservative surgery started radiotherapy
within 1 or 2 days after surgery. Time between surgery and radio-
therapy has been shown to be an important parameter and this
may also explain the higher DFI in that study.
The DFI in cats treated with surgery/brachytherapy/ALVAC IL-2
was >730 days. This value is one of the highest reported so far in
FISS [4]. It is combined with the absence of serious adverse effects
such as those occasionally reported after chemotherapy or external
radiotherapy.
Control group did not receive any placebo. Cats with FISS are at
risk of developing tumours after traumatisms or injections causing
inﬂammation in the subcutis. Injecting a placebo was therefore not
acceptable from an ethical standpoint and could have biased the
ﬁnal results. This phenomenon was reported in the efﬁcacy trial
with Vero-huIL-2 in cats [10]. Cats receiving Vero cells not express-
ing IL-2 relapsed within 3 months.
It may then be speculated that the anti-tumour efﬁcacy of
ALVAC IL-2 was mediated by the vector itself. ALVAC is indeed able
to stimulate innate immunity and induce the production of pro-
inﬂammatory cytokines with potential anti-tumour activity
[18,19]. However, treatment of human patients with metastatic
melanoma or cutaneous metastases of other cancers with ALVAC
expressing either IL-2, IL-12 or GM-CSF resulted in different clini-
cal outcomes and immunological effects [17,20]. In particular,
tumour cellular inﬁltrates and local production of IFNc depended
upon the expressed transgene. Interestingly, tumour regression
was more frequent with ALVAC-IL-2 than with the other
candidates.
In addition, the efﬁcacy of local IL-2 therapy against FISS has
been shown with other delivery systems like Vero cells [10] and
vaccinia vector [11].
Overall, this strongly suggests that the anti-tumour activity is
determined by the expression of IL-2.
Many cancers are associated with active immune suppression
and therefore immunostimulating cytokines are a potentially
attractive therapy. As a known cell growth and activation factor
for T cells and Natural Killer (NK) cells, IL-2 is one of the candidate
cytokines used in cancer immunotherapy. It was the ﬁrst cytokine
licensed by FDA for the treatment of renal cell carcinoma and
malignant melanoma. Efﬁcacy of IL-2 is however limited by the
toxic effects of the large doses required for effective therapy.
Adverse effects of systemic treatment may be overcome by local
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systems or viral vectors (eg. adenovirus, poxvirus). It has been well
established in murine models that local delivery of IL-2 in tumours
(intra-tumoural injection or administration in the tumour bed after
surgery) may be an effective alternative [21,22]. Local IL-2 therapy
has been shown to work against various tumours (ﬁbrosarcoma,
melanoma, mastocytoma, . . .) and in several species (cat, dog, cat-
tle, human) [16]. Anti-tumour effect of local IL-2 was usually asso-
ciated with the stimulation of CD4+ T cells, CD8+ T cells or NK cells,
and production of IFNc [17,20,23–26]. Since ALVAC IL-2 was
administered after surgical excision of the tumour in client-owned
cats, it was not possible to assess the local immunological effects of
the treatment. Intra-tumoural administration of ALVAC-IL-2 in
human patients with melanoma metastases resulted in a peri-
tumoural inﬁltration with CD3, CD4 and CD8-positive T cells [17].
ALVAC IL-2 treatment was well tolerated even at the highest
dose tested. The mild adverse reactions recorded in treated cats
were consistent with the safety proﬁle of ALVAC-based vaccines
in cats. In those patients, however, it cannot be ruled out that some
of these reactions were caused by the brachytherapy treatment
and the stress associated with it. As the result of the localized
expression of low doses of IL-2, no general reaction which could
be associated with the toxicity of this cytokine was observed and
the hematological and biochemical parameters remained
unchanged. Safety is often a concern with anti-cancer therapies.
The good tolerance of ALVAC IL-2 is therefore a key parameter in
the beneﬁt/risk balance of the product.
The efﬁcacy of local IL-2 as a single therapy has been demon-
strated in several tumour models [21,22,24,25,27–29] and con-
ﬁrmed in cancer patients [17,20,30–33]. Local IL-2 induced 63%
of complete regression in cattle with bovine ocular squamous cell
carcinomas [15,32] and had clear therapeutic effect in dogs with
unresectable mastocytoma [34]. Intra-tumoural administration of
ALVAC-IL-2 in human patients with cutaneous metastases of mel-
anoma or leiomyosarcoma resulted in partial regression in 3 out of
8 patients [17]. In face of highly aggressive tumours like FISS, sur-
gical excision remains the primary treatment of choice and IL-2
alone is not expected to be sufﬁcient.5. Conclusion
Despite aggressive surgery and radiotherapy, FISS remains a
therapeutic challenge. The high rate of relapse usually leads to the
euthanasia of the cat. As an adjunct therapy to surgery and brachy-
therapy, ALVAC IL-21 was shown to be both efﬁcacious and safe.
This study conﬁrmed that local IL-2 therapy may be efﬁcacious
against accessible tumours. Its efﬁcacy as an adjunct therapy
would deserve further investigations in other cancers.Disclaimer
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